A Phase 2 interventional study of Rituximab and Bendamustine in Chronic Lymphocytic Leukemia (CLL), sponsored by MedImmune LLC. Completed at 54 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-05-31.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 2, and was the 6th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
AstraZeneca · Sites in Belarus
Ages 18+
AstraZeneca · Sites in France
AstraZeneca · Sites in United States, Australia, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 103 across the 29 interventional studies, 136 across the 12 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
5 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT06548152AstraZenecaAQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database | 2026-12-31 |
| NCT05140369AstraZenecaCLL Therapy Approaches in Russia | 2027-03-31 |
| NCT06205498AstraZenecaAcalabrutinib Real World Italian obSErvational Study -ARISE | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rituximab was administered by IV infusion as 375 mg/m\^2 on Day 2 of Cycle 1 and then 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
Drug: Rituximab · Drug: Bendamustine
MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
Drug: Bendamustine · Drug: MEDI-551
MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
Drug: Bendamustine · Drug: MEDI-551
Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
Also known as: Rituxan; MabThera
Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Objective Response Rate
ORR, defined as the proportion of participants with complete response (CR) or partial response (PR) out of total number of participants. Responses were assessed by using National Cancer Institute - Working Group guidelines on CLL.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug (MEDI-551). A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 90 that were absent before treatment or that worsened relative to pre-treatment state. An AESIs was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through Day 90 after the last dose of study drug.Hepatic function abnormality and infusion reactions resulting in discontinuation were considered as AESIs.
Time frame: From time of consent to 90 days post last dose
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.
Time frame: From time of consent to 90 days post last dose
Number of Participants With Abnormal Vital Signs and Electrocardiogram Reported as AEs
AEs observed in participants with clinically significant ECG abnormalities were assessed.
Time frame: From time of consent to 90 days post last dose
Complete Response Rate
Complete response was as per IWG was the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Minimal Residual Disease Negative Complete Response (CR) Rate
The MRD-negative CR rate was defined as the percentage of participants who achieved CR and became MRD-negative as determined by flow cytometry. CR as per International Working Group (IWG) was complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Time to Response
Time to response was evaluated using the Kaplan-Meier method.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Time to Disease Progression (TTP)
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Progression Free Survival (PFS)
PFS was measured from the start of treatment with study drug until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Overall Survival (OS)
OS was determined as the time from the start of treatment with study drug until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA)
A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.
Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Terminal Half Life (t1/2) of MEDI-551
Terminal phase elimination half-life (T1/2) was the time required for half of the drug to be eliminated from the serum.
Time frame: Pre-infusion and 1 hour post infusion on Days 2 and 8, Days 15 and 22 of cycle 1
| Milestone | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Started | 62 | 36 | 61 |
| Completed | 33 | 12 | 36 |
| Not completed | 29 | 24 | 25 |
| Withdrew: Disease progression | 2 | 2 | 0 |
| Withdrew: Adverse event | 14 | 13 | 17 |
| Withdrew: Withdrawal of consent | 2 | 0 | 0 |
| Withdrew: Investigator discretion | 3 | 2 | 2 |
| Withdrew: Randomized-not treated | 2 | 3 | 4 |
| Withdrew: Other-unspecified | 6 | 4 | 2 |
ORR, defined as the proportion of participants with complete response (CR) or partial response (PR) out of total number of participants. Responses were assessed by using National Cancer Institute - Working Group guidelines on CLL.
| Percentage of Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Objective Response Rate | 59.7 (46.4 to 71.9) | 52.8 (35.5 to 69.6) | 63.9 (50.6 to 75.8) |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug (MEDI-551). A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 90 that were absent before treatment or that worsened relative to pre-treatment state. An AESIs was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through Day 90 after the last dose of study drug.Hepatic function abnormality and infusion reactions resulting in discontinuation were considered as AESIs.
| Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| TEAEs | 58 | 33 | 57 |
| TESAEs | 19 | 16 | 19 |
| AESIs | 2 | 4 | 6 |
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.
| Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Hyperbilirubinaemia | 0 | 2 | 1 |
| Hypercalcaemia | 1 | 0 | 0 |
| Hypercholesterolaemia | 1 | 0 | 1 |
| Hyperglycaemia | 4 | 2 | 1 |
| Hyperkalaemia | 2 | 1 | 2 |
| Hyperlipidaemia | 0 | 1 | 0 |
| Hypermagnesaemia | 1 | 0 | 0 |
| Hyperphosphataemia | 0 | 1 | 1 |
| Hypertriglyceridaemia | 1 | 0 | 0 |
| Hyperuricaemia | 3 | 5 | 2 |
| Hypoalbuminaemia | 2 | 0 | 2 |
| Hypocalcaemia | 3 | 1 | 1 |
| Hypokalaemia | 6 | 1 | 4 |
| Hypomagnesaemia | 2 | 2 | 1 |
| Hyponatraemia | 2 | 1 | 0 |
| Alanine Aminotransferase Increased | 1 | 0 | 3 |
| Aspartate Aminotransferase Increased | 1 | 0 | 3 |
| Blood Alkaline Phosphatase Increased | 1 | 1 | 2 |
| Blood Bilirubin Increased | 0 | 1 | 1 |
| Blood Cholesterol Decreased | 0 | 0 | 1 |
| Blood Creatinine Decreased | 1 | 0 | 0 |
| Blood Creatinine Increased | 1 | 2 | 1 |
| Blood Immunoglobulin G Decreased | 0 | 0 | 1 |
| Blood Lactate Dehydrogenase Increased | 4 | 0 | 0 |
| Blood Urea Increased | 1 | 1 | 0 |
| Gamma-Glutamyltransferase Increased | 1 | 1 | 2 |
| Hepatic enzyme Increased | 1 | 0 | 0 |
| Anaemia | 18 | 7 | 9 |
| Eosinophilia | 0 | 0 | 1 |
| Lymphopenia | 4 | 3 | 1 |
| Neutropenia | 28 | 10 | 19 |
| Thromobocytopenia | 12 | 6 | 10 |
| Activated Partial Thromboplastin Time Prolonged | 2 | 0 | 0 |
| Blood Fibrinogen Increased | 1 | 0 | 0 |
| Blood Immunoglobulin g Decreased | 0 | 0 | 1 |
| Haemoglobin Decreased | 0 | 1 | 0 |
| Lymphocyte Count Decreased | 3 | 0 | 2 |
| Neutrophil Count Decreased | 9 | 1 | 3 |
| Platelet Count Decreased | 2 | 2 | 3 |
| Prothrombin Time Shortened | 1 | 0 | 0 |
| Haematuria | 0 | 2 | 1 |
| Proteinuria | 0 | 1 | 0 |
| White Blood Cells in Urine | 0 | 0 | 1 |
AEs observed in participants with clinically significant ECG abnormalities were assessed.
| Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Atrial Fibrillation | 1 | 2 | 1 |
| Atrioventricular Block | 1 | 0 | 0 |
| Palpitations | 0 | 0 | 2 |
| Sinus Bradycardia | 1 | 0 | 0 |
| Sinus Tachycardia | 1 | 0 | 0 |
| Tachycardia | 2 | 1 | 1 |
| Pyrexia | 20 | 11 | 14 |
| Dyspnoea | 9 | 2 | 4 |
| Dyspnoea Exertional | 3 | 1 | 0 |
| Hypertension | 1 | 0 | 1 |
| Hypotension | 5 | 2 | 6 |
| Orthostatic Hypotension | 0 | 0 | 1 |
Complete response was as per IWG was the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
| Percentage of Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Complete Response Rate | 6.5 (1.8 to 15.7) | 5.6 (0.7 to 18.7) | 11.5 (4.7 to 22.2) |
The MRD-negative CR rate was defined as the percentage of participants who achieved CR and became MRD-negative as determined by flow cytometry. CR as per International Working Group (IWG) was complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
| Percentage of Participants | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Minimal Residual Disease Negative Complete Response (CR) Rate | 1.6 (0.0 to 8.7) | 5.6 (0.7 to 18.7) | 4.9 (1.0 to 13.7) |
Time to response was evaluated using the Kaplan-Meier method.
| Months | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Time to Response | 2.1 (1.9 to 2.6) | 1.9 (1.7 to 2.9) | 2.1 (1.9 to 3.5) |
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death.
| Months | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Time to Disease Progression (TTP) | 15.4 (12.0 to 27.2) | 15.0 (5.8 to 23.3) | 16.1 (12.5 to 24.0) |
PFS was measured from the start of treatment with study drug until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation.
| Months | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Progression Free Survival (PFS) | 14.8 (11.4 to 23.5) | 15.0 (5.8 to 22.1) | 16.1 (12.5 to 21.6) |
OS was determined as the time from the start of treatment with study drug until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.
| Months | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (23.9 to NA) |
A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.
| Participants | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|
| Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA) | 4 | 8 |
Terminal phase elimination half-life (T1/2) was the time required for half of the drug to be eliminated from the serum.
| Day | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|
| Terminal Half Life (t1/2) of MEDI-551 | 17.2 ± 9.56 | 22.0 ± 14.4 |
Collected over From start of study drug administration until 90 days after the last dose of study drug. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Bendamustine | — | 19/60 (31.7%) | 58/60 (96.7%) |
| MEDI-551 2 mg/kg + Bendamustine | — | 16/33 (48.5%) | 31/33 (93.9%) |
| MEDI-551 4 mg/kg + Bendamustine | — | 19/57 (33.3%) | 54/57 (94.7%) |
| Event | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 1/60 | 5/33 | 5/57 |
| PneumoniaInfections and infestations | 1/60 | 4/33 | 1/57 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/60 | 0/33 | 2/57 |
| SepsisInfections and infestations | 3/60 | 1/33 | 0/57 |
| VomitingGastrointestinal disorders | 2/60 | 0/33 | 0/57 |
| Abdominal lymphadenopathyBlood and lymphatic system disorders | 0/60 | 1/33 | 0/57 |
| LymphadenopathyBlood and lymphatic system disorders | 0/60 | 1/33 | 1/57 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/60 | 1/33 | 1/57 |
| Anaphylactic reactionImmune system disorders | 0/60 | 1/33 | 1/57 |
| BronchitisInfections and infestations | 1/60 | 1/33 | 1/57 |
| Event | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 14/60 | 21/33 | 37/57 |
| NauseaGastrointestinal disorders | 29/60 | 13/33 | 29/57 |
| NeutropeniaBlood and lymphatic system disorders | 28/60 | 10/33 | 19/57 |
| FatigueGeneral disorders | 18/60 | 14/33 | 20/57 |
| ConstipationGastrointestinal disorders | 20/60 | 9/33 | 10/57 |
| AstheniaGeneral disorders | 20/60 | 4/33 | 7/57 |
| PyrexiaGeneral disorders | 20/60 | 11/33 | 14/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/60 | 5/33 | 19/57 |
| AnaemiaBlood and lymphatic system disorders | 18/60 | 7/33 | 9/57 |
| DiarrhoeaGastrointestinal disorders | 13/60 | 5/33 | 11/57 |
Intent-to-treat (ITT) Population includes all participants who were randomized into the study.
| Age, Continuous(YEARS) | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine | TOTAL |
|---|---|---|---|---|
| Mean | 63.4 ± 8.8 | 65.1 ± 8.7 | 66.3 ± 8.9 | 65.1 ± 8.8 |
| Sex: Female, Male(Participants) | Rituximab + Bendamustine | MEDI-551 2 mg/kg + Bendamustine | MEDI-551 4 mg/kg + Bendamustine | TOTAL |
|---|---|---|---|---|
| Female | 16 | 14 | 18 | 48 |
| Male | 46 | 22 | 43 | 111 |
The record gives a start of Feb 2012, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab
Leukemia, Lymphocytic, Chronic, B-Cell →